How Does Vazalore Work? Mechanism of Action Explained in Plain English

Aspirin has been used in medicine since the late 1800s, and its general mechanism of action is well established. But Vazalore adds a layer of complexity: a novel drug delivery system designed to change how aspirin moves through your body. To understand Vazalore, you need to understand both how aspirin works and why the delivery method matters so much.

How Does Aspirin Work? The Basic Science

Aspirin belongs to the class of drugs called NSAIDs (non-steroidal anti-inflammatory drugs). It works through a specific and irreversible mechanism:

Aspirin permanently blocks two enzymes called COX-1 and COX-2 (cyclooxygenase-1 and cyclooxygenase-2). These enzymes are responsible for producing chemicals called prostaglandins and thromboxanes in the body:

Prostaglandins are involved in pain signaling, fever response, and inflammation. By blocking COX, aspirin reduces these signals — which is why it relieves pain and lowers fever.

Thromboxane A2 is produced by platelets (the cells in your blood that form clots). It signals platelets to clump together. By irreversibly blocking COX-1, aspirin permanently disables the platelet's ability to produce thromboxane A2 — preventing platelets from aggregating and forming dangerous clots.

Because platelets cannot regenerate COX-1 (they have no nucleus), aspirin's antiplatelet effect lasts for the lifetime of the platelet — approximately 7–10 days. This is why people take a daily aspirin for heart protection: the steady daily dose keeps the platelet pool continuously inhibited.

Why Does the Delivery System Matter?

For aspirin to work, it needs to be absorbed into the bloodstream. But that absorption process can be disrupted by the formulation. Here's the problem with common aspirin types:

Immediate-release (plain) aspirin: Dissolves directly in the stomach. Rapid and complete absorption, but causes direct contact with the stomach lining. The acidic aspirin molecule irritates the gastric mucosa, disrupting the stomach's protective phospholipid layer and leading to erosions, ulcers, and bleeding over time.

Enteric-coated aspirin: Has a protective coating designed to prevent dissolution in the acidic stomach and delay release until the less-acidic small intestine. This reduces direct stomach exposure, but the coating significantly slows and reduces absorption — sometimes by 2–4 hours. In patients with diabetes, delayed gastric emptying, or obesity, absorption can be erratic and incomplete.

How Does PLxGuard Technology Work in Vazalore?

Vazalore's PLxGuard technology takes a different approach. Instead of coating the aspirin with an acid-resistant shell, it mixes the aspirin with a phospholipid — a fat molecule that is naturally found in the body and in the protective mucus layer of the stomach.

Here's what happens inside the capsule:

The aspirin is dissolved in a liquid formulation combined with a phospholipid (lecithin) and other excipients, all enclosed in a gelatin capsule.

When swallowed, the capsule passes through the stomach without releasing its contents — the acidic stomach environment does not dissolve the liquid-filled capsule.

The capsule reaches the duodenum (first part of the small intestine), where it dissolves and releases the aspirin-phospholipid complex.

The phospholipid reduces direct mucosal contact and irritation, while the aspirin is rapidly absorbed from the intestinal lining into the bloodstream.

The result: absorption speed and reliability equivalent to immediate-release aspirin, with stomach protection comparable to enteric-coated aspirin. Vazalore essentially bridges the gap between these two existing formulations.

What Does the Clinical Research Show?

Clinical pharmacokinetic (PK) and pharmacodynamic (PD) studies have demonstrated:

Vazalore 81 mg achieved potent and early inhibition of platelet aggregation, with antiplatelet effect seen within approximately 1 hour

Enteric-coated aspirin took approximately 2+ hours to begin antiplatelet activity in the same studies

Vazalore 325 mg demonstrated bioequivalence to immediate-release aspirin in a clinical study submitted to the FDA for sNDA approval

A 2011 study in the American Journal of Gastroenterology showed the aspirin-phospholipid complex caused fewer gastroduodenal ulcers and erosions than plain immediate-release aspirin

Why Does Vazalore's Absorption Speed Matter for Heart Patients?

For patients on daily aspirin for secondary prevention, the goal is complete and consistent platelet inhibition — every single day. Research has documented "aspirin resistance" or incomplete platelet inhibition in a subset of patients on enteric-coated aspirin, particularly those with diabetes or certain metabolic conditions. Unreliable absorption means some days, the aspirin isn't doing its full job. Vazalore's more reliable absorption profile addresses this concern.

To learn more about how to use Vazalore, including dosing and who should take it, see our companion guide: What Is Vazalore? Uses, Dosage, and What You Need to Know.